ClinicalTrials.gg
RecruitingNCT07535554Updated Apr 17, 2026

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

A Phase 2/3 interventional study of [18F]AlF-FAPI-74 PET/CT in Fever of Unknown Origin, IgG4 Related Disease and Axial Spondylarthritis (axSpA), sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 2/3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2025, registered Mar 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study to evaluate the performance of new [18F]-AlF-FAPI-74 PET/CT in three inflammatory disorders (fever of unknown origin, IgG4-related disease and axial spondyloarthritis) and compare with the current stand-of-care [18F]-FDG PET/CT

02

Conditions studied

  • Fever of Unknown Origin
  • IgG4 Related Disease
  • Axial Spondylarthritis (axSpA)
  • Inflammation of Unknown Origin
03

In context

Fever of Unknown Origin

21 studies on the registry are indexed under Fever of Unknown Origin; 2 are open to participants now.

Browse Fever of Unknown Origin studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria FUO:

  • An illness of more than 3 weeks' duration,
  • Temperature exceeding 38.3°C on > 3 occasions, or elevated inflammatory markers on > 3 occasions
  • Diagnosis uncertain despite appropriate investigations.

Inclusion criteria IgG4-RD:

  • High clinical suspicion of IgG4-RD by an experienced clinician of Internal Medicine, based on anamnesis, physical examination, first-line investigations and blood tests.
  • Patients with a new diagnosis of IgG4-RD on histopathology and need for further assessment of disease extent with PET/CT,
  • Relapse of diagnosed IgG4-RD on histopathology according to an experienced clinician of Internal Medicine

Inclusion criteria AxSpA:

  • High clinical suspicion of axial spondyloarthropahy according to an experienced rheumatology (based on inflammary back pain > 3 months, insidious onset, morning stifness, improvement with exercise and worsening in rest, pain worse at night, age at onset \<45 years of age, imaging findings).
  • Patient has persisting inflammatory back pain after 2 different types of NSAID's (tried for over 2-4 weeks), and is therefore eligible for biological DMARDS therapy.

Exclusion Criteria:

  • Participant is mentally or legally incapacitated, doesn't understand the study design or is not willing or capable to undergo all study-specific procedures.
  • Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
  • Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.
  • Female who is pregnant (urinary hCG test will be performed in every ), breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).
  • Participation in an interventional Trial with an medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.
  • Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.
  • Participant has a known to [18F]AlF-FAPI-74 or the used .
  • Active treatment has already commenced
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    FUO/IUO

    Diagnostic Test: [18F]AlF-FAPI-74 PET/CT

  • Experimental
    IgG4-related disease

    Diagnostic Test: [18F]AlF-FAPI-74 PET/CT

  • Experimental
    Axial Spondyloarthritis

    Diagnostic Test: [18F]AlF-FAPI-74 PET/CT

Interventions

  • Diagnostic test[18F]AlF-FAPI-74 PET/CT

    A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven). The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. If the patient receives therapy (for IgG4-RD and AxSpA), a second \[18F\]AlF-FAPI-74 PET/CT will be performed three months later.

06

What researchers measure

Primary outcomes

  1. FUO/IUO: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is equivalent or superior to the current gold standard, [18F] FDG PET/CT, in contributing to the final diagnosis (non-inferiority study with non-inferiority limit (10%)

    Time frame: 6 months after completion of both PET/CT scans

  2. IgG4-RD: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is superior to [18F]FDG PET/CT, in patients with suspicion of IgG4-RD and assessment of disease extent in patients with confirmed or relapsed IgG4-RD.

    Time frame: After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.

  3. Axial Spondyloarthritis: evaluate the diagnostic accuracy of [18F]AlF-FAPI-74 PET/CT in differentiating inflammatory back pain in patients with axSpA from patients with mechanical back pain, and evaluate the ability to assess treatment response

    Time frame: After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment

Secondary outcomes

  1. FUO/IUO: Determine the distribution of the four major causal group in FUO/IUO (infectious, inflammatory, malignant, and miscellaneous) of both tracers and evaluate for which causal groups [18F]AlF-FAPI-74 PET/CT is superior to [18F]FDG PET/CT.

    Time frame: 6 months after completion of all PET/CT scans

  2. FUO/IUO: Evaluate for which entities [18F]AlF-FAPI-74 has the potential to outperform [18F]FDG PET/CT in lager patient cohorts.

    Time frame: 6 months after completion of all PET/CT scans

  3. FUO/IUO: Determine the ratio of true positives, true negatives, false positives, false negative, positive predictive value, and negative predictive value.

    Time frame: 6 months after completion of all PET/CT scans

  4. IgG4-RD: Semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), average SUV (SUVmean), peak SUV (SUVpeak) of lesions on [18F]AlF-FAPI-74 PET/CT and [18F]FDG PET/CT.

    Time frame: After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.

  5. IgG4-RD: Evaluate the organ detection ratio for every organ, defined as the percentage of patients with pathological uptake in that specific organ by each tracer for the total of number of patients with pathological uptake in that organ

    Time frame: After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.

  6. IgG4-RD: 4) Evaluate the total number of affected organs per patient for each tracer and calculate the difference for both tracers. Determine the total difference of affected organs between both tracers for all patients.

    Time frame: After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.

  7. IgG4-RD: Evaluate the treatment response of FAPI and FDG lesions by quantifying the change in SUVmax between baseline and post-therapy PET/CT scans.

    Time frame: After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.

  8. AxSpA: Semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), target-to-background (TBR)) of lesions in the spine and the sacro-iliac joints will be computed on [18F]AlF-FAPI-74 PET/CT in all patients

    Time frame: After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment

  9. AxSpA: Determine if there is a significant statistical difference (p<0.05) in semi-quantitative uptake measurements (SUVmax, TBR) between the two cohorts, and determine the optimal cut-off value.

    Time frame: After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment

  10. AxSPa: Assess treatment response by evaluating changes in semi-quantitative measurements (SUVmax, TBR) in patients with axSpA following 3 month treatment with bDMARDs.

    Time frame: After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Mar 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 17, 2026
StartActual
Sep 17, 2025
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2030
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535554
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Sep 17, 2025
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Apr 17, 2026

Study contacts

Lennert Boeckxstaens, MD
Contact
lennert.boeckxstaens@uzleuven.be
+0032 16 34 37 15

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion